North Star Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

North Star Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$618	Hold	13	–	–	﹤0.01%	1561
2025 Q4	$682	Hold	13	–	–	﹤0.01%	1424
2025 Q3	$843	Hold	13	–	–	﹤0.01%	1181
2025 Q2	$632	Hold	13	–	–	﹤0.01%	1149
2025 Q1	$442	Hold	13	–	–	﹤0.01%	1149
2024 Q4	$512	Hold	13	–	–	﹤0.01%	1168
2024 Q3	$611	Hold	13	–	–	﹤0.01%	1131
2024 Q2	$702	Hold	13	–	–	﹤0.01%	1107
2024 Q1	$886	Hold	13	–	–	﹤0.01%	1165
2023 Q4	$814	Hold	13	–	–	﹤0.01%	1121
2023 Q3	$590	Hold	13	–	–	﹤0.01%	1189
2023 Q2	$730	Hold	13	–	–	﹤0.01%	1190
2023 Q1	$588	Hold	13	–	–	﹤0.01%	1224
2022 Q4	$528	Hold	13	–	–	﹤0.01%	1234
2022 Q3	$1K	Hold	13	–	–	﹤0.01%	1069
2022 Q2	$1K	Hold	13	–	–	﹤0.01%	1076
2022 Q1	$1K	Hold	13	–	–	﹤0.01%	1090
2021 Q4	$1K	Sell	13 -600	-98%	-$52.4K	﹤0.01%	1119
2021 Q3	$69K	Hold	613	–	–	0.01%	531
2021 Q2	$99K	Buy	613 +300	+96%	+$36.5K	0.01%	482
2021 Q1	$38K	Buy	313 +300	+2,308%	+$45.3K	﹤0.01%	600
2020 Q4	$2K	Buy	+13	New	+$1.54K	﹤0.01%	952

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

North Star Investment Management's CRSP Position: Q1 2026 in Review

North Star Investment Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 13 shares worth $618. The position accounts for ﹤0.01% of the portfolio, ranked #1561.

North Star Investment Management first reported a position in CRSP in Q4 2020 and has held it in 22 quarters since. The position peaked at $99K in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

North Star Investment Management held 13 shares of CRISPR Therapeutics worth $618 as of Q1 2026.
North Star Investment Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up ﹤0.01% of North Star Investment Management's portfolio in Q1 2026, its #1561 holding.
North Star Investment Management first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 22 quarters since.
North Star Investment Management's CRISPR Therapeutics position peaked at $99K in Q2 2021.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on North Star Investment Management's 13F filing for Q1 2026, filed 23 Apr 2026.